<DOC>
	<DOCNO>NCT01698788</DOCNO>
	<brief_summary>This study undertaken determine effect sustain release dexamethasone implant , Ozurdex improve outcome taut posterior hyaloid removal patient diabetic macular edema Diabetic macular edema constitute important cause visual impairment patient diabetes.Focal/ grid laser photocoagulation standard care management . Several adjunct include intravitreal corticosteroid , Pegaptanib Sodium , Ranibizumab , Bevacizumab also tried.In patient inspite multiple laser injection macular edema persists consequence overlie taut posterior hyaloid membrane need remove vitrectomy . Visual improvement vitrectomy related duration edema , well extent intraretinal lipid vascular nonperfusion.Even surgery patient might need repeat intravitreal bevacizumab triamcinolone injection take care residual macular edema.Intravitreal Triamcinolone Acetonide ( TA ) , water insoluble steroid , show reduce retinal thickness improve visual acuity . However , recurrence macular edema patient receive intravitreal TA major concern short half life . In search ideal corticosteroid preparation , Dexamethasone Posterior Segment Drug Delivery System ( Dexamethasone DDS - Ozurdex® , Allergan Inc , Irvine , California ) recently develop generate new interest molecule . It sustain release intravitreal implant contain 700µg dexamethasone approve US-FDA ( Food Drug Administration ) treatment macular edema retinal vein occlusion . The present study introduces novel concept use intraoperative Ozurdex ® implant taut posterior hyaloid removal effect improve surgical outcome</brief_summary>
	<brief_title>Effect Intraoperative Dexamethasone Implant Taut Posterior Hyaloid Removal Diabetic Macular Edema</brief_title>
	<detailed_description>This study undertaken determine effect sustain release dexamethasone implant , Ozurdex improve outcome taut posterior hyaloid removal patient diabetic macular edema Diabetic macular edema constitute important cause visual impairment patient diabetes.Focal/ grid laser photocoagulation standard care management .Several adjunct include intravitreal corticosteroid , Pegaptanib Sodium , Ranibizumab , Bevacizumab also tried.In patient inspite multiple laser injection macular edema persists consequence overlie taut posterior hyaloid membrane need remove vitrectomy . The exact role vitreous pathogenesis diabetic maculopathy remain unclear although implicate cause macular edema via several mechanical physiologic mechanism , include follow ( 1 ) destabilization vitreous abnormal glycation crosslinking vitreal collagen , lead traction macula , ( 2 ) accumulation concentration factor cause vasopermeability premacular vitreous gel ( 3 ) accumulation chemoattractant factor vitreous , leading cellular migration posterior hyaloid , contraction macular traction . The observation release mechanical traction macula subsequent reduction DME , either spontaneous posterior vitreous detachment vitrectomy , lend support line reason . Furthermore , evidence vitrectomy produce improved retinal oxygenation take together evidence increase oxygenation reduce DME , suggest additional physiologic advantage determination eye might benefit vitrectomy challenge aspect treatment condition . Fluorescein angiography , B-scan ultrasonography , optical coherence tomography may helpful regard . Most often , vitreous surgery perform diabetic macular edema persist despite multiple laser treatment . All report publish date regard vitrectomy diabetic macular edema uncontrolled nonrandomized patient series . Visual improvement vitrectomy related duration edema , well extent intraretinal lipid vascular nonperfusion.Even surgery patient might need repeat intravitreal bevacizumab triamcinolone injection take care residual macular edema.Intravitreal Triamcinolone Acetonide ( TA ) , water insoluble steroid , show reduce retinal thickness improve visual acuity . However , recurrence macular edema patient receive intravitreal TA major concern short half life . In search ideal corticosteroid preparation , Dexamethasone Posterior Segment Drug Delivery System ( Dexamethasone DDS - Ozurdex® , Allergan Inc , Irvine , California ) recently develop generate new interest molecule . It sustain release intravitreal implant contain 700µg dexamethasone approve US-FDA ( Food Drug Administration ) treatment macular edema retinal vein occlusion . The present study introduces novel concept use intraoperative Ozurdex ® implant taut posterior hyaloid removal effect improve surgical outcome</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Vision Disorders</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Type 1 2 Diabetes mellitus 2 . TPHM cause cystoid macular edema without subfoveal serous RD OCT 1 . Known case ocular hypertension glaucoma 2 . Macular ischemia FFA</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>diabetic macular edema</keyword>
	<keyword>taut posterior hyaloid membrane</keyword>
	<keyword>ozurdex</keyword>
</DOC>